Takada Kohichi, Murase Kazuyuki, Nakamura Hajime, Hayasaka Naotaka, Arihara Yohei, Iyama Satoshi, Ikeda Hiroshi, Emori Makoto, Sugita Shintaro, Nakamura Katsuyuki, Miyanishi Koji, Kobune Masayoshi, Kato Junji
Department of Medical Oncology, Sapporo Medical University School of Medicine, Japan.
Department of Hematology, Sapporo Medical University School of Medicine, Japan.
Intern Med. 2019 Oct 15;58(20):3009-3012. doi: 10.2169/internalmedicine.2790-19. Epub 2019 Jun 27.
Pneumothorax has been reported as a pazopanib-associated adverse event in patients with lung metastases of soft tissue sarcoma (STS). However, pneumothorax triggered by eribulin treatment has never been reported. We herein report two cases of spontaneous pneumothorax in patients with STS treated with eribulin. Both patients experienced pneumothorax accompanied by sudden dyspnea on day 9 or 10 of eribulin treatment. These two cases suggest that spontaneous pneumothorax may occur as an adverse event of eribulin treatment in such patients. We should therefore be alert for the potential development of pneumothorax during eribulin treatment of patients with STS and lung metastases.
气胸已被报道为软组织肉瘤（STS）肺转移患者使用帕唑帕尼相关的不良事件。然而，依维莫司治疗引发的气胸从未被报道过。我们在此报告两例接受依维莫司治疗的STS患者发生自发性气胸的病例。两名患者均在依维莫司治疗的第9天或第10天出现气胸并伴有突发呼吸困难。这两例病例提示，此类患者使用依维莫司治疗可能会发生自发性气胸这一不良事件。因此，我们在对患有STS和肺转移的患者进行依维莫司治疗期间应警惕气胸的潜在发生。
